-
Company Profile
![]()
Genentech USA Inc – Company Profile
Genentech USA Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process, and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-3245 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGB-3245 in Colorectal Cancer Drug Details: BGB-3245 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Marstacimab in Hemophilia B (Factor IX Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Marstacimab in Hemophilia B (Factor IX Deficiency) Drug Details: Marstacimab (PF-06741086) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TP-04 in Rosacea
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TP-04 in Rosacea Drug Details:TP-04 is under development for the treatment of rosacea.Report CoverageThe data is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UI-035 in Cognitive Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.UI-035 in Cognitive DisordersDrug Details:UI-035 is under development for the treatment of cognitive disorders.Report CoverageThe data...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HCP-2102 in Idiopathic (Essential) Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2102 in Idiopathic (Essential) HypertensionDrug Details:HCP-2102 is under development for the treatment of essential hypertension.Report CoverageThe...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6537 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6537 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: RG-6537 (RO-7656594, GDC-2992) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7303509 in Systemic Sclerosis (Scleroderma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RO-7303509 in Systemic Sclerosis (Scleroderma) Drug Details:RO-7303509 is under development for the treatment of inflammation and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CG-750 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CG-750 in Idiopathic Pulmonary Fibrosis Drug Details:CG-750 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Descartes-11 in Refractory Multiple Myeloma Drug Details:Descartes-11 is developing for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6287 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RG-6287 in Inflammation Drug Details:RG-6287 is under development for the treatment of inflammatory bowel disease, graft...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7303509 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RO-7303509 in Inflammation Drug Details:RO-7303509 is under development for the treatment of inflammation and systemic sclerosis....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7446603 in Diabetic Macular Edema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RO-7446603 in Diabetic Macular Edema Drug Details:RO-7446603Â is under development for the treatment of diabetic macular edema...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rapirosiran Sodium in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Rapirosiran Sodium in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Rapirosiran (ALN-HSD) is under development for the treatment of non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Deudomperidone in Diabetic Gastroparesis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Deudomperidone in Diabetic GastroparesisDrug Details:Deudomperidone (CIN-102) is under development for the treatment of idiopathic and diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-001 in Osteoarthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.G-001 in OsteoarthritisDrug Details:G-001 is under development for the treatment of knee osteoarthritis. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TJCLDN-4B in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TJCLDN-4B in Gastric Cancer Drug Details: TJ-033721 is under development for the treatment of gastric...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Multiple Myeloma (Kahler Disease)Drug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TK-001 in Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TK-001 in Breast Cancer Drug Details: TK-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Bile Duct Cancer (Cholangiocarcinoma)Drug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.